Free Trial

Nuvectis Pharma (NVCT) Insider Trading & Ownership

Nuvectis Pharma logo
$7.47
-0.42 (-5.32%)
(As of 10/31/2024 ET)

Nuvectis Pharma (NASDAQ:NVCT) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
35.78%
Number Of
Insiders Buying
(Last 12 Months)
2
Amount Of
Insider Buying
(Last 12 Months)
$80,470.60
Number Of
Insiders Selling
(Last 12 Months)
0
Get NVCT Insider Trade Alerts

Want to know when executives and insiders are buying or selling Nuvectis Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

NVCT Insider Buying and Selling by Quarter

Nuvectis Pharma Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/14/2024Ron BentsurCEOBuy1,940$6.74$13,075.60  
5/10/2024Enrique PoradosuInsiderBuy500$6.29$3,145.00  
5/10/2024Ron BentsurCEOBuy2,000$6.40$12,800.00  
3/18/2024Ron BentsurCEOBuy5,000$10.29$51,450.00  
(Data available from 1/1/2013 forward)

NVCT Insider Trading Activity - Frequently Asked Questions

The list of insiders at Nuvectis Pharma includes Enrique Poradosu, Kenneth Hoberman, Marlio Charles Mosseri, Ron Bentsur, and Shay Shemesh. Learn more on insiders at NVCT.

35.78% of Nuvectis Pharma stock is owned by insiders. Learn more on NVCT's insider holdings.

The following insiders have purchased NVCT shares in the last 24 months: Enrique Poradosu ($8,920.00), Marlio Charles Mosseri ($2,936,894.14), Ron Bentsur ($209,368.35), and Shay Shemesh ($17,101.50).

Insiders have purchased a total of 198,691 NVCT shares in the last 24 months for a total of $3,172,283.99 bought.



This page (NASDAQ:NVCT) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners